Drugs: Intellectual Property

(asked on 6th November 2017) - View Source

Question to the Department of Health and Social Care:

To ask Her Majesty's Government what incentives, if any, they plan to introduce to ensure that, following Brexit, firms continue to develop intellectual property in the UK, including for paediatric products and orphan medicines; and whether, in so doing, they will take into account any recommendations arising out of the European Commission’s current analysis of intellectual property incentives for the pharmaceutical industry.


Answered by
Lord O'Shaughnessy Portrait
Lord O'Shaughnessy
This question was answered on 20th November 2017

The Prime Minister has made clear that a key priority through the negotiations will be to ensure that the United Kingdom remains one of the best places in the world for science and innovation. Part of this will be ensuring an effective Intellectual Property (IP) regime that supports UK innovation and creativity. The UK will remain one of the best places in the world to obtain and protect IP.

The Government has contributed to the European Commission’s ongoing analysis of intellectual property incentives for the pharmaceutical sector and will want to consider its recommendations in due course. The Government’s European Union Withdrawal Bill is designed to ensure that the UK exits the EU with certainty, continuity, and control, ensuring that, so far as possible, the same rules and laws will apply on the day after exit as on the day before.

Reticulating Splines